Longitudinal clinical course and long-term outcomes of SLE-associated interstitial lung disease
Lupus Science and Medicine, cilt.13, sa.2, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13 Sayı: 2
- Basım Tarihi: 2026
- Doi Numarası: 10.1136/lupus-2026-002304
- Dergi Adı: Lupus Science and Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals, Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: Autoimmune Diseases, Pulmonary Fibrosis, Systemic Lupus Erythematosus
- Bursa Uludağ Üniversitesi Adresli: Evet
Özet
Objectives: Interstitial lung disease (ILD) is a clinically important manifestation of SLE, and its longitudinal course and prognostic factors remain poorly characterised. We evaluated the longitudinal course, long-term outcomes and prognostic utility of the Goh staging system in SLE-ILD. Methods: This multicentre observational cohort included 42 patients with chronic SLE-ILD. ILD severity was classified using the Goh staging system, and longitudinal pulmonary function and high-resolution CT (HRCT) changes were assessed. The primary outcome was ILD progression during the first 24 months, defined as a ≥10% decline in forced vital capacity (FVC) and/or radiological progression on HRCT. Long-term pulmonary events were analysed using competing-risk methods, with death treated as a competing event; overall survival was evaluated using Kaplan-Meier and Cox regression. Results: At baseline, 24 patients (57.1%) had limited and 18 (42.9%) had extensive ILD. During the first 24 months, ILD progression occurred in 2 of 42 patients (4.8%). Among patients with extensive ILD, 8 of 18 (44.4%) were reclassified as limited, while one patient (4.2%) progressed from limited to extensive ILD. Longitudinal mixed-effects analysis demonstrated significant improvement in FVC in patients with extensive ILD (adjusted mean increase, 6.7 percentage points; 95% CI 0.7 to 12.6; p=0.03). Over a median follow-up of 52 months, ILD progression occurred in four patients (9.5%), acute exacerbation in three (7.1%) and death in eight (19.0%). Overall survival estimates differed between Goh groups, although the Cox estimate was imprecise (HR 4.74, 95% CI 0.87 to 25.71). Conclusions: SLE-ILD generally followed a favourable long-term course, with most patients achieving radiological and functional stability or improvement. The Goh staging system provided an exploratory framework for assessing long-term outcomes, whereas longitudinal follow-up suggested that disease extent may improve over time. These findings support integrated HRCT and pulmonary function assessment for longitudinal evaluation in SLE-ILD.